ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2020
Effect of Saccharomyces boulardii CNCM I-745 as complementary treatment of Helicobacter pylori infection on gut microbiome.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04786938 (Effect of Saccaromyces Boulardii CNCM I-745 Supplementation on the Fecal Resistome of Patients Treated Against Helicobacter Pylori Infection), which is not on this map. Cited by 27 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Saccaromyces Boulardii CNCM I-745 Supplementation on the Fecal Resistome of Patients Treated Against Helicobacter Pylori Infection
Who cites it
27 citing papers in PubMed, 3 syntheses or guidelines pooled it, 57 citations in OpenAlex.
- Pooled it
- The effect of supplementing withFrontiers in medicine · 2024Pooled it
- Probiotic supplementation during antibiotic treatment is unjustified in maintaining the gut microbiome diversity: a systematic review and meta-analysis.BMC medicine · 2023Pooled it
- Saccharomyces boulardii combined with triple therapy alter the microbiota in the eradication of Helicobacter pylori infection.Scientific reports · 2024Trial
- Trial
- Effect of Probiotic-Assisted Eradication ofBioMed research international · 2022Trial
- Therapeutic Potential of Probiotics in the Modulation of Antibiotic Resistance inBiomedicines · 2026Review
- Article
- Nutritional Status and Fecal Microbiota in School Children from the Galapagos and the Andean Region.Microbial ecology · 2025Article
- Towards EffectiveInternational journal of molecular sciences · 2025Review
- Integrated 16S rDNA-Seq and metabolomics reveal seasonal dynamics of gut microbial-SCFA-immune crosstalk in diarrheic calves.Frontiers in veterinary science · 2025Article
- Butyric Acid Supplementation Reduces Changes in the Taxonomic and Functional Composition of Gut Microbiota Caused byMicroorganisms · 2024Article
- Human Gut Microbiota in Heart Failure: Trying to Unmask an Emerging Organ.Biomedicines · 2023Review
- Microbiome-Related and Infection Control Approaches to Primary and Secondary Prevention ofMicroorganisms · 2023Review
- The Influence ofAntibiotics (Basel, Switzerland) · 2023Review
- Recent developments in the production and utilization of photosynthetic microorganisms for food applications.Heliyon · 2023Review
- The efficacy and safety ofTherapeutic advances in gastroenterology · 2023Article
- Article
- The Effect of Quadruple Therapy with Polaprezinc or Bismuth on Gut Microbiota afterJournal of clinical medicine · 2022Article
- Are pro- and/or synbiotics beneficial in Helicobacter pylori eradication therapy in children? A narrative review.European journal of pediatrics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
Conventional therapy for H. pylori infection includes the combination of antibiotics and a proton-pump inhibitor. Addition of probiotics as adjuvants for H. pylori antibiotic treatment can increase eradication rate and decrease treatment side effects. Although many studies show the benefits of S. boulardii CNCM I-745 in the treatment of H. pylori infection, the mechanism by which those benefits are achieved is unknown. Here, we report clinical characteristics and fecal microbiota changes comparing conventional anti-H. pylori therapy versus conventional therapy supplemented with S. boulardii CNCM I-745. A total of 74 patients were included in the current study; patients positive for H. pylori (n = 63) were randomly assigned to 2 groups: 34 patients received conventional therapy and 29 antibiotic therapy plus 750 mg of S. boulardii CNCM I-745 daily, for 2 weeks. Eleven patients negative for H. pylori infection were also studied. Patients provided 3 fecal samples: before initiating the antibiotic treatment, upon its completion, and 1 month after treatment. Patients were contacted every 72 h to inquire about side effects and compliance. DNA was extracted, and 16S rRNA was amplified and sequenced on Illumina MiSeq. Bioinformatic analysis was performed using QIIME2. Patients who received the probiotic had a significantly lower frequency of associated gastrointestinal symptoms (P = 0.028); higher number of bacterial diversity evenness (P = 0.0156); higher abundance of Enterobacteria; and lower abundance of Bacteroides and Clostridia upon treatment completion. Addition of S. boulardii CNCM I-745 induced a lower frequency of gastrointestinal symptoms that could be related to changes in gut microbiota.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.